Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 02 2020
25 02 2020
Historique:
received:
21
05
2019
accepted:
07
02
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
21
11
2020
Statut:
epublish
Résumé
Although guidelines recommend BRCA testing for all women with non-mucinous epithelial ovarian cancer, there is significant variability in access to testing across the UK. A germline BRCA mutation (BRCAm) in ovarian cancer patients provides prognostic and predictive information and influences clinical management, such as the use of PARP inhibitors, which have demonstrated a progression-free survival benefit in the BRCAm cohort. Additionally, the finding of a BRCAm has significant implications for patients and their families in terms of cancer risk and prevention. We studied the impact of a newly-formed, oncologist-led 'mainstreaming' germline BRCA testing pathway in 255 ovarian cancer patients at Imperial College NHS Trust. Prior to the establishment of 'mainstreaming', uptake of germline BRCA testing was 14% with a mean turnaround time of 148.2 calendar days. The 'mainstreaming' approach led to a 95% uptake of germline BRCA testing and a mean turnaround time of 20.6 days. Thirty-four (13.33%) BRCAm patients were identified. At the time of data collection nine BRCAm patients had received a PARP inhibitor off-trial, three had entered a PARP inhibitor trial and 5 were receiving platinum-based chemotherapy with a plan to receive PARP inhibitor maintenance. This study provides further evidence of the impact of oncologist-led 'mainstreaming' programs.
Identifiants
pubmed: 32098980
doi: 10.1038/s41598-020-60149-5
pii: 10.1038/s41598-020-60149-5
pmc: PMC7042365
doi:
Substances chimiques
BRCA1 Protein
0
BRCA2 Protein
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Platinum
49DFR088MY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3390Références
Ovarian cancer statistics. Cancer Research UK https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer#heading-Zero (2018).
Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117–1130 (2003).
doi: 10.1086/375033
Lewis, K. E., Lu, K. H., Klimczak, A. M. & Mok, S. C. Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. Cancers. 10, 57 (2018).
doi: 10.3390/cancers10020057
Candido-dos-Reis, F. et al. Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clin. Cancer Res. 21(3), 652–657 (2015).
doi: 10.1158/1078-0432.CCR-14-2497
George, A. et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci. Rep. 6, 29506 (2016).
doi: 10.1038/srep29506
Alsop, K. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group. J. Clin. Oncol. 30(21), 2654–2663 (2012).
doi: 10.1200/JCO.2011.39.8545
Zhang, S. et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol. Oncol. 121(2), 353–357 (2011).
doi: 10.1016/j.ygyno.2011.01.020
Rahman, B. et al. Mainstreamed genetic testing for women with ovarian cancer: First-year experience. J. Med. Genet. 56, 195–198 (2019).
doi: 10.1136/jmedgenet-2017-105140
Pal, T. et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 104(12), 2807–2816 (2005).
doi: 10.1002/cncr.21536
Kentwell, M. et al. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol. Oncol. 145(1), 130–136 (2017).
doi: 10.1016/j.ygyno.2017.01.030
Plaskocinska, I. et al. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. J. Med. Genet. 53(10), 655–661 (2016).
doi: 10.1136/jmedgenet-2016-103902
Fox, E. et al. The sooner the better: Genetic testing following ovarian cancer diagnosis. Gynecol. Oncol. 137(3), 423–429 (2015).
doi: 10.1016/j.ygyno.2015.03.057
George, A., Kaye, S. & Banerjee, S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat. Rev. Clin. Oncol. 14(5), 284–296 (2017).
doi: 10.1038/nrclinonc.2016.191
Demsky, R. et al. Keeping it simple: Genetics referrals for all invasive serous ovarian cancers. Gynecol. Oncol. 130(2), 329–333 (2013).
doi: 10.1016/j.ygyno.2013.05.003
Lynparza (olaparib). European Medicines Agency https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza (2018).
NICE Technology appraisal guidance [TA381]. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy. National Institute for Health and Care Excellence (NICE) https://www.nice.org.uk/guidance/ta381/chapter/1-Recommendations (2018).
Colombo, N. et al. Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. J. Clin. Oncol. 36(13), 1300–1307 (2018).
doi: 10.1200/JCO.2017.76.2781
Percival, N. et al. The integration of BRCA testing into oncology clinics. Br. J. Nurs. 25(12), 690–694 (2016).
doi: 10.12968/bjon.2016.25.12.690
Mirza, M. et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N. Engl. J. Med. 375(22), 2154–2164 (2016).
doi: 10.1056/NEJMoa1611310
Coleman, R. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 390(10106), 1949–1961 (2017).
doi: 10.1016/S0140-6736(17)32440-6
Moore, K. et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
doi: 10.1056/NEJMoa1810858
Vergote, I. et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur. J. Cancer 69, 127–134 (2016).
doi: 10.1016/j.ejca.2016.10.006
NICE Clinical guideline [CG164]. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. National Institute for Health and Care Excellence (NICE) https://www.nice.org.uk/guidance/cg164 (2018).
Achieving world class cancer outcomes: A strategy for England 2015–2020. Independent Cancer Taskforce https://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf (2018).
Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15(8), 852–861 (2014).
doi: 10.1016/S1470-2045(14)70228-1
Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18(9), 1274–1284 (2017).
doi: 10.1016/S1470-2045(17)30469-2